SEOM clinical guidelines for anaemia treatment in cancer patients (2020)

Clin Transl Oncol. 2021 May;23(5):931-939. doi: 10.1007/s12094-021-02580-2. Epub 2021 Mar 25.

Abstract

Anaemia is defined by the presence of haemoglobin (Hb) levels < 13 g/dL in men and 12 g/dL in women. Up to 39% of cancer patients present it at the time of diagnosis and up to 40% have iron deficiency. Anaemia causes fatigue, functional deterioration and a reduction in the quality of life; it has also been associated with a poorer response to anti-tumour treatment and lower survival. Basic diagnostic tests for anaemia are simple and should be a routine part of clinical practice. These guidelines review the available evidence on the use of different therapies for treating anaemia: erythropoiesis-stimulating agents, iron supplements, and transfusion of blood products.

Keywords: Anaemia; Erythropoiesis stimulating agents; Iron supplements; Transfusion of blood products.

Publication types

  • Practice Guideline

MeSH terms

  • Algorithms
  • Anemia / blood
  • Anemia / complications
  • Anemia / diagnosis*
  • Anemia / therapy*
  • Anemia, Iron-Deficiency / complications
  • Anemia, Iron-Deficiency / diagnosis
  • Diagnosis, Differential
  • Dietary Supplements / adverse effects
  • Erythrocyte Transfusion / adverse effects
  • Erythrocyte Transfusion / methods
  • Female
  • Hematinics / adverse effects
  • Hematinics / therapeutic use*
  • Humans
  • Iron / administration & dosage*
  • Iron / adverse effects
  • Male
  • Medical Oncology
  • Neoplasms / complications*
  • Neoplasms / mortality
  • Quality of Life
  • Societies, Medical
  • Spain

Substances

  • Hematinics
  • Iron